Pharmaceutical compositions

• US 5,593,665 A
• Filed: 05/17/1994
• Issued: 01/14/1997
• Est. Priority Date: 03/15/1990
• Status: Expired due to Term

• Current Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Original Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Inventors: Pfirrmann, Rolf W., Geistlich, Peter
• Primary Examiner(s): Sayala, Chhaya D.
• Application Number:
  US08/243,739
• Time in Patent Office: 973 Days
• Field of Search: 424/85.1, 514/422
• US Class Current: 424/85.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/54 having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
• CPC Class Codes: A61K 38/191 Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The invention provides products containing tumour necrosis factor (TNF), and taurolidine and/or taurultam as a combined preparation for simultaneous, separate or sequential use for treatment of patients suffering from medical conditions mediated by TNF.

Claims

1. In combination:

tumour necrosis factor (TNF) and a member selected from the group consisting of taurolidine, taurultam and a mixture thereof, for simultaneous, separate or sequential use for treatment of patients suffering from medical conditions mediated by TNF.

2. A combination as claimed in claim 1 comprising said TNF and said member selected from the group consisting of taurolidine, taurultam and a mixture thereof, in a preparation for sequential administration of said TNF and said member.

3. A method of treatment of medical conditions mediated by TNF comprising administering to a patient suffering from one or more said conditions effective amounts of TNF and a member selected from the group consisting of taurolidine, taurultam and a mixture thereof.

4. A method of treatment as claimed in claim 3, wherein said effective amounts of TNF and of said member selected from the group consisting of taurolidine, taurultam and a mixture thereof, are co-administered.

5. A pharmaceutical composition comprising TNF and a member selected from the group consisting of taurolidine, taurultam and a mixture thereof.

6. A process of manufacturing a pharmaceutical composition, wherein TNF is admixed with a member selected from the group consisting of taurolidine, taurultam and a mixture thereof.

7. A method of reducing toxic effects of TNF in a human or non-human animal body, comprising administering to a human or non-human animal body at least one member selected from the group consisting of taurolidine, taurultam, and a mixture thereof, so as to reduce toxic effects of TNF in said body.

8. A method of treatment of a patient suffering from TNF-producing tumor or obstructive jaundice, thereby resulting in a chronic, detectable amount of TNF in the patient'"'"'s blood comprising administering an effective amount of a member selected from the group consisting of taurolidine, taurultam or a mixture thereof, to the patient.